Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers

    loading  Checking for direct PDF access through Ovid



To investigate the effect of tetracycline co-administration on the pharmacokinetics of halofantrine in healthy subjects.


Eight healthy males were each given 500 mg single oral doses of halofantrine alone, or with tetracycline (500 mg 12 hourly for 7 days), in a crossover fashion. Blood samples collected at predetermined intervals were analyzed for halofantrine and its major metabolite, desbutylhalofantrine (HFM), using a validated HPLC method.


Co-administration of tetracycline and halofantrine resulted in a significant increase (P < 0.05) in the maximum plasma concentration (Cmax), total area under the concentration-time curve (AUC), and terminal elimination half-life (t1/2,z), compared with halofantrine alone. (Cmax 0.43 ± 0.14 vs 1.06 ± 0.44 μg ml−1 (95% CI on the difference 0.30, 0.95); AUC 32.0 ± 13.6 vs 63.7 ± 20.1 μg ml−1 h (95% CI 14.2, 49.1); t1/2,z: 90.8 ± 17.9 vs 157.4 ± 57.4 h (95% CI 21.7, 111.5)). Similarly, tetracycline caused a significant increase (P < 0.05) in the AUC and Cmax of HFM.


Tetracycline co-administration significantly increases the plasma concentrations of halofantrine and its major metabolite.

Related Topics

    loading  Loading Related Articles